NCT04074785

Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6

Pilot Study of Abemaciclib With Bevacizumab in Recurrent Glioblastoma Patients With Loss of CDKN2A/B or Gain or Amplification of CDK4/6

• Status: Terminated
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of Texas Southwestern Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

Describe the safety and adverse events associated with Abemaciclib 150 mg orally twice daily when administered with Bevacizumab 10 mg/kg intravenously every 2 weeks to recurrent GBM patients with specific tumor molecular aberrations

Conditions

• GBM
• Glioblastoma
• Brain Tumor
• Brain Tumor, Recurrent

Interventions

Type	Name	Description
DRUG	Abemaciclib	Abemaciclib 150 mg po bid
DRUG	Bevacizumab	Bevacizumab 10 mg/kg IV every 2 weeks, then continue treatments for 2 cycles

Timeline

• Start date: 2019-12-13
• Primary completion: 2023-10-16
• Completion: 2023-10-16
• First posted: 2019-08-30
• Last updated: 2025-08-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study